TuHURA Biosciences, Inc./NV

TuHURA Biosciences announced its 2026 Annual Meeting of Stockholders will be held virtually on August 18, 2026. Due to the change in the meeting date by more than 30 days from the prior year's special meeting, the previous deadlines for shareholder proposals and director nominations no longer apply. New deadlines for all submissions, including Rule 14a-8 proposals and proxy access nominations, are set for June 27, 2026.

TuHURA Biosciences, Inc. announced it received its first draw of $1,700,000 on May 26, 2026, under the previously disclosed revolving credit facility with Parkview Holdings One LLC. The company plans to use these funds for general corporate purposes. The revolving credit facility, established on April 21, 2026, has a maximum loan availability of $50 million and matures on April 21, 2031.

TuHURA Biosciences reported a net loss of $7.54 million for the first quarter of 2026, an increase from $6.66 million in the prior year. Despite the wider loss, the company's cash and cash equivalents significantly increased to $6.30 million, driven by $7.50 million in proceeds from common stock issuance. The company anticipates its current capital resources will fund operations until the end of 2028.

TuHURA Biosciences reported its first quarter 2026 financial results and provided a corporate update, highlighted by securing a $50 million non-equity-based credit facility and royalty transaction. This financing extends the company's anticipated cash runway into 2028, allowing it to fund operations beyond anticipated top-line data in its lead IFx-2.0 program. The company also announced key management appointments and received FDA Orphan Drug Designation for IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma, alongside outlining several upcoming pipeline milestones.

TuHURA Biosciences, Inc. filed an amendment to its prior Form 8-K to correct errors in the unaudited pro forma condensed combined financial statements for the year ended December 31, 2025. These statements reflect the completed acquisition of Kineta, Inc. on June 30, 2025, as if it occurred on January 1, 2025. The pro forma net loss for the year was $(34,469,964), resulting in a net loss per share of $(0.66). The acquisition had an estimated purchase price of $16,560,163, including significant in-process research and development and goodwill. Additionally, the company completed a private placement in June 2025, raising $11,512,169 in net proceeds.

TuHURA Biosciences reported a net loss of $(30.1) million for the year ended December 31, 2025, increasing from $(21.7) million in 2024, with an accumulated deficit of $141.2 million. The company had $3.6 million in cash and cash equivalents as of year-end and expects current funds to last through Q2 and into Q3 2026, necessitating substantial additional funding. The filing also details recent financing activities, including a $15.6 million registered direct offering and a $12.6 million private placement, and the acquisition of Kineta, Inc. in June 2025. This 10-K/A amends the original 10-K to include Part III information and correct errors in the MD&A.

TuHURA Biosciences, Inc. entered into a $50 million revolving credit facility with Parkview Holdings One LLC, an affiliate of its largest stockholder. The facility, maturing in April 2031, will fund general corporate purposes, including ongoing clinical trials and development programs. Borrowings will bear interest at 12% per annum and are secured by substantially all company assets. This funding is expected to provide sufficient capital into the first half of 2027, contingent on stockholder approval for Loan Fee Shares.

TuHURA Biosciences' Compensation Committee approved significant performance bonuses for its top executives for 2025, recognizing their contributions. Dr. James Bianco, President and CEO, received a bonus of $490,536, while CFO Dan Dearborn was awarded $163,393. Additionally, both executives received a 5% cost-of-living increase to their annual base salaries, reflecting ongoing adjustments to compensation. The filing also noted the context of updated pro forma financial statements related to the previously completed acquisition of Kineta, Inc. on June 30, 2025, which was initially announced via a merger agreement in December 2024.